𝕏xSE first seen 8 h ago, last 7 h ago, peak #32
Retatrutide Phase 3 Trial Shows Up to 25% Weight Loss
Original: Retatrutide Trial Shows Up to 25% Weight Loss in Phase 3 Study
Eli Lilly's obesity drug retatrutide delivered weight loss of up to 25% in a Phase 3 clinical trial, according to reported results. The injectable, which targets multiple hormone receptors, is being positioned as a potential rival to tirzepatide and semaglutide in the fast-growing weight-loss drug market, drawing attention from patients and analysts.
Why now: New Phase 3 results suggest a potential next-generation obesity treatment, fueling interest in the booming weight-loss drug race.
Rank over time, top of the chart is #1. 4 snapshots from 8 h ago to 7 h ago.
API: https://socialmediatrends-api.osmike.com/v1/trends/408226